Die membranöse Glomerulonephritis – entscheidende Fortschritte in der Diagnostik und Therapie

Schlüsselwörter

membranöse Glomerulonephritis - nephrotisches Syndrom - Autoantikörper - Phospholipase-A2-Rezeptor

Keywords

membranous nephropathy - nephrotic syndrome - autoantibodies - phospholipase A2 receptor

• Literatur

• 1 Beck Jr LH. Membranous nephropathy and malignancy. Semin Nephrol 2010; 30: 635-644
• 2 Beck Jr LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
• 3 Cattran D. Management of membranous nephropathy: When and what for treatment?. J Am Soc Nephrol 2005; 16: 1188-1194
• 4 Cattran DC, Greenwood C, Ritchie S et al. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 1995; 47: 1130-1135
• 5 Dähnrich C, Komorowski L, Probst C et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013; 421: 213-218
• 6 Frei U, Schober-Halstenberg HJ. Bericht über Dialysebehandlung und Nierentransplantation in Deutschland 2006/2007. Berlin: QuaSi-Niere; 2008: 35
• 7 Glassock RJ. The pathogenesis of membranous nephropathy: evolution and revolution. Curr Opin Nephrol Hypertens 2012; 21: 235-242
• 8 Hofstra JM, Debiec H, Short CD et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1735-1743
• 9 Hoxha E, Harendza S, Zahner G et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26: 2526-2532
• 10 Hoxha E, Kneißler U, Stege G et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82: 797-804
• 11 Hoxha E, Thiele I, Zahner G et al. Phospholipase A2 Receptor autoantibody levels and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014; im Druck
• 12 Kerjaschki D. Pathomechanisms and molecular basis of membranous glomerulonephritis. Lancet 2004; 364: 1194-1196
• 13 Leaf DE, Appel GB, Radhakrishnan J. Glomerular disease: why is there a dearth of high quality clinical trials?. Kidney Int 2010; 78: 337-342
• 14 Polanco N, Gutiérrez E, Covarsí A et al. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010; 21: 697-704
• 15 Ponticelli C, Altieri P, Scolari F et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998; 9: 444-450
• 16 Qin W, Beck Jr LH, Zeng C et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1137-1143
• 17 Ruggenenti P, Cravedi P, Chianca A et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23: 1416-1425
• 18 Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010; 363: 496-498